Abex Zlin spol. s r.o.
- Address
- Nam. T. G. Masaryka 1280, 760 01 Zlín, Czechia
Abex Zlin spol. s r.o. - Advanced Breast Cancer Research Center
Abex Zlin spol. s r.o. is a specialized clinical research facility focused on advancing treatment options for patients with hormone receptor-positive breast cancer. The center demonstrates particular expertise in studying targeted therapies for complex, treatment-resistant breast cancer subtypes that have progressed despite standard therapeutic approaches.
- Advanced breast cancer with ESR1 mutations and resistance to CDK4/6 inhibitors
- Combination therapies involving selective estrogen receptor degraders and mTOR inhibitors
- Hormone receptor-positive, HER2-negative breast cancer progression
The research center specializes in phase 3 clinical trials evaluating novel therapeutic combinations for ER+/HER2- advanced breast cancer with ESR1 mutations. Their work addresses critical unmet needs in patients who have experienced progression on endocrine therapy combined with CDK4/6 inhibitors, exploring innovative strategies such as combining elacestrant with everolimus to overcome treatment resistance and improve progression-free survival outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Abex Zlin spol. s r.o.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Elacestrant and Everolimus in ER+/HER2-, ESR1-Mutated Advanced Breast Cancer Post-Endocrine and CDK4/6 Inhibitors | Medica Scientia Innovation Research S.L., Stemline Therapeutics Inc. | Phase III | Recruiting | Dec 2024 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Betamethasone Sodium Phosphate | 1 | Unknown | 2024-12-12 | 2024-12-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.